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Summary 
Background Initial results from the ongoing GALLIUM trial have shown that patients with 
follicular lymphoma have a longer progression-free survival after first-line 
immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary 
analysis was to evaluate the prognostic value of PET–CT responses after first-line 
immunochemotherapy in the GALLIUM study. 
Methods GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which 
recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1–3a; 
disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years 
or older and met the criteria for needing treatment. Eligible patients were randomly assigned 
in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, 
and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m² on day 1 of each 
cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone 
(known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or 
eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral 
administration), or six 28-day cycles with bendamustine, followed by maintenance antibody 
every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed 
progression-free survival, has been reported previously. This secondary analysis reports PET 
and CT-based responses at end-of-induction therapy and explains their relation with 
progression-free and overall survival outcomes in patients with available scans. As per 
protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with 
available PET facilities, and optional thereafter), acquired at baseline and end of 
induction (PET population), were assessed prospectively by investigators and an independent 
review committee (IRC) applying International Harmonisation Project (IHP) 2007 response 
criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. 
IRC members (but not study investigators) were masked to treatment and clinical outcome 
when assessing response. The landmark analyses excluded patients who died or 
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progressed (contrast enhanced CT-based assessment of progressive disease, or started next 
anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at 
ClinicalTrials.gov, number NCT01332968. 
Findings 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, 
of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 
508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival 
(landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6–69·4]) 
achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 
72·0–79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. 
With a median of 43·3 months of observation (IQR 36·2–51·8), 2·5-year progression-free 
survival from end of induction was 87·8% (95% CI 83·9–90·8) in PET complete responders 
and 72·0% (63·1–79·0) in non-complete responders according to IRC-assessed IHP 2007 
criteria (hazard ratio [HR] 0·4, 95% CI 0·3–0·6, p<0·0001). According to Lugano 2014 
criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% 
(95% CI 83·7–90·2) and in non-complete metabolic responders was 54·9% (40·5–67·3; HR 
0·2, 95% CI 0·1–0·3, p<0·0001). 
Interpretation Our results suggest that PET is a better imaging modality than contrast-
enhanced CT for response assessment after first-line immunochemotherapy in patients with 
follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a 
platform for investigation of response-adapted therapeutic approaches. Additional supportive 
data are welcomed. 
Funding F. Hoffmann-La Roche. 
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Research in context 
Evidence before this study 
On Dec 12, 2017, we searched PubMed using combinations of the terms “fluorodeoxyglucose 
OR fludeoxyglucose OR 2-fluoro-2-deoxy-d-glucose OR 2-[F-18]-fluoro-2-deoxy-D-glucose 
OR FDG OR 18F-FDG OR positron emission tomography OR positron emission 
tomography-computed tomography OR PET OR PET–CT OR PET/CT”, “follicular 
lymphoma OR FL OR indolent”, “prognostic OR prognosis”, “predictive”, “progression-free 
survival OR PFS”, and “overall survival OR OS”, with no restrictions on language. Several 
studies have suggested that 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET response at the 
end of induction therapy is prognostic for progression-free survival in patients with follicular 
lymphoma primarily treated with first-line R-CHOP (rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone) without maintenance therapy. There is also some 
evidence that end of induction PET response could be prognostic for overall survival, 
although small sample sizes have prevented a robust assessment. In this secondary analysis of 
the GALLIUM trial, the first randomised study to compare first-line immunochemotherapy 
with obinutuzumab versus rituximab plus maintenance therapy in patients with follicular 
lymphoma, we further investigate the potential prognostic role of PET in this setting. 
Added value of this study 
This secondary analysis from GALLIUM provides prospective PET data from a large 
population of patients with follicular lymphoma receiving a wide spectrum of modern 
immunochemotherapies, including bendamustine-based treatment and different anti-CD20 
maintenance antibodies. The results of retrospective analysis applying the current, 
internationally accepted Lugano 2014 response criteria (which incorporates the ordinal 5-
point scale [Deauville criteria] for evaluating PET scans) presented here suggests that, for 
patients with follicular lymphoma, achieving a complete metabolic response is prognostic for 
improved progression-free and overall survival in this indolent but heterogeneous lymphoma. 
These data support the use of end-of-induction PET response status as a practical, early 
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predictor of progression-free and overall survival, helping to identify patients with the 
greatest risk of relapse. 
Implications of all the available evidence 
Evidence from this secondary analysis and previous studies suggest PET as a superior 
imaging modality compared with contrast-enhanced CT for response assessment in patients 
with follicular lymphoma treated with first-line immunochemotherapy. PET-response 
assessment at the end of induction therapy could inform patients and their clinicians of the 
probability of both progression-free and overall survival. The data also support the use of PET 
assessment according to Lugano 2014 response criteria as a platform to study response-
adapted therapeutic approaches in future clinical trials to improve outcomes for patients with 
follicular lymphoma. 
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Introduction 
Follicular lymphoma is the most common indolent non-Hodgkin lymphoma, and has 
heterogeneous clinical behaviour. Follicular lymphoma is highly sensitive to initial therapy, 
but is characterised by recurrent relapses and risk of histological transformation. In the 
modern era of combined immunochemotherapy, with the promise shown with the type 2 
anti-CD20 antibody obinutuzumab in the ongoing GALLIUM trial in this setting,
1 the 
lengthy remission and overall survival for some patients (possibly beyond 20 years after 
diagnosis) now challenges the perception of follicular lymphoma as incurable.
2,3 
Many 
patients are more likely to die from other causes while in remission or with asymptomatic 
disease than from the diagnosed follicular lymphoma itself. Nonetheless, a substantial 
minority of patients (approximately 20%) have a poor prognosis, and these patients are not 
reliably identified at diagnosis by conventional response assessment based on CT and bone 
marrow analyses.
4,5 There is preliminary evidence from studies suggesting that 2-18F-fluoro-
2-deoxy-D-glucose (18F-FDG) PET–CT response after induction therapy is prognostic for 
outcomes in follicular lymphoma. Findings from three prospective studies of first-line 
immunochemotherapy for high-tumour-burden follicular lymphoma showed almost universal 
18F-FDG uptake in follicular lymphoma, and progression-free survival was significantly 
longer in those patients with a negative PET at end of treatment compared with those with a 
positive PET.
4,6,7 In one study, patients remaining PET positive had a significantly 
(p=0·001) inferior progression-free survival at 42 months of 32·9% (95% CI 17·2–49·5) 
compared with 70·7% (59·3–79·4) in those who became PET  negative.
4 
In  another  study, 
with a median follow-up of 23 months, 2-year progression-free survival was 51% for patients 
who remained PET-positive versus 87% for patients who became PET-negative (p<0·001).
6 
In the third study, with a median follow-up of 34 months, the 3-year progression-free survival 
was 35% and 66%, respectively, for patients with positive and negative postinduction PET 
(p<0·001).
7 
A pooled analysis of these studies with longer follow-up was conducted; scans 
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were centrally reviewed by three independent PET physicians. Post-treatment PET with a 
cutoff score of four or greater (defined as ¹⁸F-FDG uptake in tumour higher than that in the 
liver) on the 5-point scale (also known as the Deauville criteria)
8,9 was prognostic (4-year 
progression-free survival was only 23·2% [95% CI 11·1–37·9] in patients remaining PET-
positive, compared with 63·4% [55·9–70·0] for those who had a negative postinduction-
PET; p<0·0001). Patient numbers were too small and duration of follow-up too short to make 
robust estimates of overall survival (4-year overall survival was 87·2%  [95%  CI  71·9–94·5]  
vs  97·1%  [93·2–98·8], respectively; p<0·0001).
5 Furthermore, most of these patients did 
not receive rituximab maintenance, which has been shown to provide a progression-free 
survival benefit after first-line treatment. The findings from these studies led to a 
recommendation by the International Conference on Malignant Lymphomas Imaging 
Working Group to include follicular lymphoma in the most recent Lugano 2014 classification 
for response assessment of ¹⁸F-FDG-avid lymphomas (lymphomas that take up FDG during 
PET scans), which incorporated the established cutoff score on the 5-point scale.
4,5,7,8,10–15
  
The phase 3 GALLIUM study (NCT01332968) was designed to compare the 
efficacy and safety of induction therapy with obinutuzumab versus induction therapy with 
rituximab, combined with chemotherapy (bendamustine, CHOP [cyclophosphamide, 
doxorubicin, vincristine, and prednisone], or CVP [cyclophosphamide, vincristine, and 
prednisone]) in both groups and followed by maintenance with the same antibody alone, in 
responding patients with previously untreated, advanced, indolent non-Hodgkin lymphoma. 
The study was powered to evaluate investigator-assessed progression-free survival in 
patients with follicular lymphoma, enrolling 1202 such patients between July 6, 2011 and 
Feb 4, 2014. Despite a similar proportion of patients achieving an overall response based 
on contrast- enhanced CT assessment, obinutuzumab chemotherapy and maintenance 
significantly reduced the risk of relapse, progression, or death compared with rituximab 
chemotherapy and maintenance (hazard ratio [HR] 0·66, 95% CI 0·51–0·85, p=0·001), thus 
meeting the primary endpoint of the study (no medians were reached).
1 
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On the basis of the above mentioned findings from several cohort studies suggesting the 
prognostic value of post-treatment PET in follicular lymphoma,
4−7,10 we hypothesised that 
patients with follicular lymphoma who achieved PET negativity in the GALLIUM trial could 
have better prognosis in terms of both progression-free and overall survival than PET-positive 
patients. The aim of the current prespecified secondary analysis was to evaluate the PET 
response at end of induction with immunotherapy and to explore its prognostic value in patients 
with follicular lymphoma treated within the GALLIUM study. 
 
Methods 
Study design and participants 
This is a secondary analysis of PET results from GALLIUM, an ongoing randomised, 
open-label, parallel-group, phase 3 trial. An early protocol amendment on July 26, 2011 
made PET mandatory at baseline and at the end-of-induction therapy for a minimum of 170 
patients recruited for the GALLIUM trial at sites where PET scanning was available, 
becoming optional thereafter. The updated study protocol is available in the appendix (pp 9–
235).  
The study design and patient population for GALLIUM including full eligibility 
criteria have been described previously.
1 Briefly, eligible patients were aged 18 years or 
older; had previously untreated, histologically confirmed, CD20-positive follicular lymphoma 
(grades 1–3a); advanced disease (stage III/IV, or stage II with largest tumour diameter ≥7 
cm); an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; adequate 
haematological function (haemoglobin ≥9·0 g/dL, absolute  neutrophil  count  ≥1·5 × 10⁹/L,  
platelet  count ≥75 × 10⁹/L); and required treatment according to Groupe d’Etude des 
Lymphomes Folliculaires criteria. Details of previous and concomitant permitted treatments 
are provided in the appendix (p 1).  
The study is being done in accordance with the International Conference on 
Harmonisation guidelines for Good Clinical Practice, and the protocol was approved by the 
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ethics committee at each participating centre. Patients provided written informed consent 
before any study-specific procedures were performed. 
 
Randomisation and masking 
During GALLIUM, patients were randomly assigned 1:1 to receive intravenous infusions of 
obinutuzumab or rituximab plus chemotherapy of choice. Randomisation was done by means 
of an interactive voice-response or online response system with the use of a hierarchical 
dynamic randomisation scheme and stratified by induction chemotherapy regimen 
(bendamustine, CHOP, or CVP), Follicular Lymphoma International Prognostic Index (FLIPI) 
risk category (low, intermediate, or high), and geographical region. The trial was open label, and 
only the independent review committee (IRC) were masked to treatment assignment. 
 
Procedures 
Patients received either intravenous infusions of obinutuzumab (1000 mg on days 1, 8, and 15 of 
cycle 1, then day 1 of subsequent cycles) plus chemotherapy of choice or rituximab (375 
mg/m² on day 1 of each cycle) plus chemotherapy of choice, for six 28-day cycles for those 
receiving bendamustine-containing chemotherapy or six 21-day cycles for those receiving 
CHOP or eight 21-day cycles for CVP as chemotherapy. Patients receiving CHOP received six 
cycles of obinutuzumab or rituximab plus CHOP and two cycles of antibody monotherapy, for 
eight cycles in total. The choice of chemotherapy was stipulated by each site, with all patients 
at that site receiving the same regimen. Doses of chemotherapy were as follows: for CHOP, 
cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and vincristine 1·4 mg/m² (maximum 
dose 2 mg) by intravenous infusion on day 1 plus prednisone 100 mg orally per day on days 1–
5 of six 21-day cycles; for CVP, the same doses of cyclophosphamide, vincristine, and 
prednisone as in CHOP for eight 21-day cycles; and for bendamustine, 90 mg/m² by 
intravenous infusion on days 1 and 2 of six 28-day cycles. 
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Patients with a CT-based complete response or partial response at end of induction 
received maintenance treatment with the antibody they received during induction (1000 mg 
obinutuzumab or 375 mg/m² rituximab) every 2 months for 2 years, or until progressive disease 
or study withdrawal; no crossover was permitted. Those with stable disease at end of induction 
were followed on the same schedule as patients receiving maintenance, but were not prescribed 
antibody maintenance. Disease assessments including CT scans were done every 4 months 
for the first year and every 6 months for the second year of maintenance. Patients were then 
followed up every 3 months for 3 years (with CT scans every 6 months), then every 6 months for 
2 years (with annual CT scans) until the end of the study or until disease progression. Patients with 
disease progression were followed up for overall survival every 6 months until the end of the 
study, and were treated at the discretion of the investigator, according to institutional practice. 
               PET scans were done at baseline (≤35 days before randomisation) and at end of 
induction (6–8 weeks after day 1 of the last cycle of chemotherapy) or early study 
termination. Scans were assessed by investigators and an IRC, comprising two radiologists 
who were masked to clinical outcome, and a third adjudicating radiologist whose role was 
to resolve any disagreements between the radiologists relating to the attributed response; 
the final IRC response was determined by an independent clinician (masked to treatment 
and outcome) who considered the final radiological response in addition to bone marrow and 
other biopsy information. 
CT and PET response was evaluated for patients achieving a partial response or 
complete response as per the International Harmonisation Project (IHP) 2007 response 
criteria.
12,13 Both investigator and IRC reporting adhered to IHP 2007 response criteria.  
According to these criteria, any end-of-induction PET with ¹⁸F-FDG uptake greater than or 
equal to uptake in the mediastinum in lesions of 2 cm or larger, or uptake greater than that of 
adjacent background tissue in lesions smaller than 2 cm, was defined as PET positive. 
These assessments were prespecified in the GALLIUM study protocol (appendix pp 9–
235). PET scans to assess metabolic response were also retrospectively assessed by the IRC 
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only according to the more recent Lugano 2014 response criteria,
8,11 incorporating the 5-
point scale as an exploratory analysis. By these criteria, positive scans were defined by a 
residual ¹⁸F-FDG uptake score of 4 or greater (ie, uptake greater than the maximum 
standardised uptake value in a large region of normal liver). In accordance with the Lugano 
2014 criteria,  recognised causes for ¹⁸F-FDG uptake other than follicular lymphoma were 
assigned as unrelated to follicular lymphoma. For CT scans, as per IHP 2007 criteria, 
patients formerly assigned to unconfirmed complete response
14 are generally classified as 
partial response. Bone marrow biopsy was done in all patients at baseline and was required in 
patients with conventional CT-based complete response at end of induction. 
 
Outcomes 
The primary endpoint of the GALLIUM trial was investigator-assessed progression-free 
survival (defined as the time from randomisation to the first occurrence of progression or 
relapse) in patients with follicular lymphoma. Key secondary efficacy endpoints were 
progression-free survival in all randomised patients, overall survival (defined as the time 
from the date of randomisation to the date of death from any cause) in all patients with 
follicular lymphoma and all randomised patients, and the proportion of patients 
achieving an overall and complete response in all patients with follicular lymphoma and 
all randomised patients, as previously reported.
1
 
This secondary analysis, which will report CT and PET-based responses at end-of-
induction therapy and explore their relation with progression-free and overall survival 
outcomes in patients with available scans, was prespecified as an exploratory analysis of 
the trial in a protocol amendment on July 26, 2011. 
 
Statistical analysis 
The data reported in the primary GALLIUM study report were from a preplanned interim 
analysis, when the prespecified significance level for the primary endpoint had been crossed 
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(cutoff Jan 31, 2016).
1 The results reported in this Article are from an updated analysis 
(cutoff Sept 10, 2016). 
As a secondary analysis of the GALLIUM trial, the analyses presented in this 
report are not powered. Demographic and baseline characteristics were summarised using 
descriptive statistics in the PET population (defined as all randomly assigned patients 
with available baseline and end-of-induction PET scans; the non-PET population included 
all other randomly assigned patients). 
Response was reported in the PET population only. Complete response was compared 
between the two treatment groups using Cochran–Mantel–Haenszel tests, with FLIPI and 
chemotherapy regimen used as stratification factors. Concordance between  response as 
assessed by investigator versus IRC with IHP 2007 criteria was assessed through cross-
tabulation tables and Cohen’s Kappa estimates. PET complete response or complete 
metabolic response was compared with baseline characteristics, including individual 
components of the FLIPI and FLIPI2 prognostic indices, conventional CT-based response, 
progression-free survival, and overall survival. Progression-free survival and overall survival 
were analysed by complete response (assessed by CT alone), complete response or 
complete metabolic response (assessed by PET) status, or both, and by treatment group. All 
patients with an end-of-induction PET available for central review were included in the IHP 
response assessment. Patients in whom baseline scans were unavailable but with end-of-
induction scans available for central review were excluded from IRC assessment in 
accordance with Lugano 2014 criteria.  
            Kaplan–Meier methodology was used to estimate landmark progression-free and 
overall survival distributions from end-of-induction therapy for each group. Landmark 
analyses of progression-free and overall survival, which considered response at a fixed point 
in time and removed patients with an event (or censored) before the landmark analysis, were 
used to avoid immortal bias.
15 
The starting point of the landmark analysis of progression-
free survival was the end-of-induction tumour assessment. Patients with progressive 
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disease before the end-of-induction assessment were excluded. The starting point for the 
landmark analysis of overall survival was the same as for the progression-free survival 
analyses, except that patients with progressive disease were not excluded. If a patient had IRC-
assessed progressive disease on the basis of IHP 2007 assessment, or any antilymphoma 
medication before the last dose of study treatment, then the start date for the landmark 
analysis was set to the randomisation date plus 180 days (the planned duration of the 
induction therapy phase). Patients with end-of-induction visits who had started 
maintenance therapy were excluded from the landmark analyses.                                                
Estimates of the differences between groups were determined using a stratified Cox 
proportional hazards analysis and expressed as HRs and 95% CIs. Estimated 2·5-year 
probabilities, including 95% CIs, were also used to describe progression-free and overall 
survival. Exploratory univariate and multivariable Cox analyses were undertaken to investigate 
factors that were prognostic for progression-free and overall survival. Investigated covariables 
included Lugano 2014 PET-based response (non-complete metabolic response [partial 
metabolic response, no metabolic response, or progressive metabolic disease] vs complete 
metabolic  response),  treatment group (rituximab chemotherapy vs obinutuzumab 
chemotherapy), and the prespecified  stratification factors: induction  chemotherapy  
(bendamustine vs CHOP or CVP), FLIPI risk category (low vs intermediate, low vs high), 
and geographical region. The covariates were entered simultaneously into the Cox model. 
The level of statistical significance was set at 0·05 (two-sided test) and analyses were done with 
SAS version 9.4. 
GALLIUM is registered at  ClinicalTrials.gov, number NCT01332968. 
 
Role of the funding source 
The funder was involved in trial design, and in data collection, analysis, and 
interpretation. Authors who were employees of the funder (TN, DS, and GRF-R) contributed 
to the writing and approval of the manuscript. JZ and DS have full access to the raw data, and all 
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authors had limited access to the data and statistical results. All authors have approved the 
final draft of the manuscript and the corresponding author had the final responsibility to submit 
for publication. 
 
Results 
Patients  were   enrolled   into   GALLIUM   between July 6, 2011, and Feb 4, 2014. The 
trial profile for the primary study population has been published previously.
1 Compared with a 
median follow-up of 34·5 months (IQR 0–54·5) in the original report, this updated analysis 
reports after a median follow-up of 43·3 months (IQR 36·2–51·8). PET scans were done in 
669 (65%) of 1029 patients enrolled after July 26, 2011, at 103 of the 177 recruiting centres 
(appendix pp 6–8). Of 609 patients with a baseline PET scan, 595 (98%) also had an end-of- 
induction scan (PET population; figure 1). Among these 595 patients, 543 (91%) qualified 
for landmark assessment of overall survival by IHP 2007 response criteria; 10 (2%) of 543 
had disease progression before the end-of-induction therapy and were excluded from 
progression-free survival analyses. 519 (87%) of 595 patients had both baseline and end-of-
induction PET scans available for central review, and qualified for landmark assessment of 
overall survival by Lugano 2014 response criteria; 11 (2%) of 519 progressed before end of 
induction and were excluded from the landmark progression-free survival analyses (figure 1). 
End-of-induction PET scans were done a median of 19 days (IQR 14–25) after 
the end of the last cycle of rituximab chemotherapy and 20 days (IQR 15–26) after the end 
of the last cycle of obinutuzumab chemotherapy.  
Baseline disease and demographic characteristics are provided in table 1. Baseline 
characteristics for patients in the  PET  IHP  2007  and  Lugano  2014  response 
populations were well balanced (appendix p 2). 
End-of-induction bone  marrow biopsy  results were available for 247 (55%) of 450 
patients who had a complete metabolic response on standard Lugano 2014 response 
assessment; of these, five (2%) patients had their response downgraded to partial 
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metabolic response due to a positive bone marrow biopsy. 
IRC-assessed end-of-induction CT response and PET response by IHP 2007 and 
Lugano 2014 response criteria for the PET population are shown in table 2. On CT 
assessment alone, the proportion of patients achieving an overall response in the PET 
population was 539 (90·6%; 95% CI 88·0–92·8) of 595 patients (table 2). When PET was 
included in the response assessment, 517 (86·9%; 95% CI 83·9–89·5) of 595 patients had 
an overall response according to IHP 2007 response criteria and 486 (81·7%; 95% CI 78·3–
84·7) of 595 according to Lugano 2014 response criteria (table 2). The proportion of patients 
achieving a PET complete response and complete metabolic response more than doubled 
compared with the proportion achieving CT complete response (table 2). Among the 
patients who qualified for the landmark analysis of progression-free survival, the proportion 
with complete metabolic response was 88% (448/508) as assessed by Lugano 2014. By IRC 
assessment, the proportion with complete response was higher for patients who received 
obinutuzumab-based chemotherapy than for those who received rituximab-based 
chemotherapy when assessed by IHP 2007 response criteria; the proportion of patients 
achieving complete metabolic response according to Lugano 2014 criteria was similar 
(tables 2, 3). For all patients, 17 patients who had a complete metabolic response did not 
have a partial response on CT assessment: four had stable disease, two had progressive 
disease, evaluation was impossible in nine patients, and data were missing in two patients. 
Investigator-assessed overall responses according to IHP 2007 response criteria in the PET 
population were achieved in 496 (83·4%; 95% CI 80·1–86·3) of 595 patients, and complete 
responses were achieved in 353 (59·3%; 55·3–63·3) patients; there was 72·4% agreement 
between investigator and IRC assessments, with a Kappa coefficient of 0·49 (95% CI 0·43–0·56). 
Overall concordance between IHP 2007 and Lugano 2014 PET assessment by IRC was 0·46 
(95% CI 0·40–0·52; appendix p 3). Patients who achieved IRC-assessed PET complete 
response according to IHP 2007 or complete metabolic response as per Lugano 2014 criteria at 
end of induction were younger than those who did not (median age 55·0 years [IQR 47·0–64·0] 
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for responders vs 60·0 years [51·0–67·0] for non-responders as per IHP 2007; p=0·0019; and 
56·0 years [47–65] for responders vs 63·0 years [52–66] for non-responders as per Lugano 2014; 
p=0·0044). A higher percentage of patients who did not achieve a complete response or 
complete metabolic response had bulky disease (≥7 cm) at baseline (79 [55%] of 144 vs 168 [43%] 
of 390, p=0·015 for complete response; and 39 [57%] vs 198 [44%], p=0·039 for complete metabolic 
response), and extranodal involvement was more common (116 [80%] for non-complete 
response vs 256 [66%] for complete response; p=0·0013 for IHP 2007 response criteria). Using 
both criteria (IHP 2007 and Lugano 2014), FLIPI was similar between patients who achieved 
complete response or complete metabolic response compared with those who did not (88 [23%] 
of 390 for complete response vs 25 [17%] of 145 for no complete response for FLIPI low; 153 
[39%] vs 54 [37%] for FLIPI intermediate; and 149 [38%] vs 66 [46%] for FLIPI high; and 94 
[21%] of 450 for complete metabolic response vs 12 [17%] of 69 for no complete metabolic 
response for FLIPI low; 178 [40%] vs 23 [33%] for FLIPI intermediate; and 178 [40%] vs 34 
[49%] for FLIPI high).  
Median observation time was 43·3 months (IQR 36·17–51·8) in the PET population. 
Having a CT-based complete response at end of induction, as assessed by the IRC, was 
significantly prognostic for progression-free survival when comparing responders versus non-
responders (figure 2A); but not for overall survival (2·5-year overall survival for patients who 
had a complete response was 97·7% [95% CI 94·0–99·1] vs 93·5% [90·5–95·6] for those 
who did not; HR 0·5, 95% CI 0·3–1·2, p=0·124). According to IRC-assessed IHP 2007 
response criteria, end-of-induction complete response status on PET was prognostic for both 
progression-free survival (figure 2B) and overall survival (2·5-year overall survival for patients 
with complete response 96·9% [95% CI 94·5–98·2] vs non-complete response 90·6% [84·6–
94·3]; HR 0·4, 95% CI 0·2–0·9, p=0·011). The results for investigator-assessed progression-free 
survival according to PET status by IHP 2007 response criteria are in the appendix (p 4). When 
the IRC applied the Lugano 2014 response criteria, end-of-induction complete metabolic 
response was also prognostic for progression-free survival (figure 2C). Patients obtaining 
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complete metabolic response at end-of-induction PET as per IRC assessment according to 
Lugano 2014 criteria also had significantly improved overall survival compared with those 
who did not (figure 3).  37 of the 519 patients included in the landmark overall survival analysis 
per PET Lugano 2014 criteria died (13 [19%] of 69 who did not have a complete metabolic 
response before the end-of-induction therapy and 24 [5%] of 450 of those who had a complete 
metabolic response). The cause of death was adverse event in 16 patients (43%), progressive 
disease in 14 (38%), and other reasons in seven (19%). Nine (13%) of 69 patients not achieving 
complete metabolic response and five (1%) of 450 achieving complete metabolic response died 
from lymphoma.  
             The improvement in progression-free survival observed in patients who achieved a 
complete metabolic response was irrespective of whether or not they achieved a complete 
response on CT (figure 4).  
Progression-free survival according to IRC-assessed PET status by Lugano 2014 
response criteria in patients who received rituximab-based chemotherapy versus those treated 
with obinutuzumab-based chemotherapy is presented in the appendix (p 5). Irrespective of the 
antibody used, having a complete metabolic response was associated with improved 
progression-free survival (at 2·5 years from end of induction, progression-free survival in 
those who achieved a complete metabolic response was 89·5% [95% CI 84·5–93·0] for 
those who received obinutuzumab vs 85·0% [95% CI 79·3–89·3] for those treated with 
rituximab; HR 0·7, 95% CI 0·4–1·1, p=0·0078). Among patients who did not achieve a 
complete metabolic response, progression-free survival at 2·5 years from end of induction 
was 69·7% (95% CI 46·5–84·3) for those treated with obinutuzumab compared with 
43·5% (95% CI 25·2–60·4) in the rituximab-treated group (HR 0·5, 95% CI 0·2–1·3, 
p=0·14). 12% (60/508) of patients in the landmark population of GALLIUM did not obtain 
complete metabolic response at the end-of-induction landmark but had a median progression-
free survival of approximately 32 months, despite the use of maintenance.  
An exploratory multivariate analysis confirmed  the univariate analysis (table 4), 
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showing that complete metabolic response status and obinutuzumab treatment group were the 
only significant independent predictors of progression-free survival. Complete metabolic 
response status was the only significant independent predictor of overall survival.  
The safety data for this updated analysis have been reported elsewhere.
16
 
 
Discussion 
This secondary analysis of GALLIUM is, to our know-ledge, the first large study of PET 
response assessment in follicular lymphoma. The secondary endpoint of PET-based response 
as assessed with the IHP 2007 response criteria was prognostic in terms of progression-free 
survival; however, the more recent Lugano 2014 response criteria served as a better tool for 
prognosis, detecting a five-times increase in risk of progression and early death in patients 
who did not achieve a complete metabolic remission compared with those who did not 
achieve a complete metabolic response. 
The proportion of patients achieving a complete metabolic response as per PET 
assessment established with the current, internationally accepted Lugano 2014 criteria,
8,11 
incorporating the 5-point scale, was more than two-times higher than the proportion achieving 
complete response determined by CT-based assessment by the IHP 2007 criteria. We 
suggest that this discrepancy between the two imaging modalities might be due to PET 
imaging more accurately distinguishing between viable lymphoma and non-lymphoma 
residual lesions than CT. Most patients who qualified for the landmark analysis achieved a 
complete metabolic response. Notably, there was a significant separation of the 
progression-free and overall survival curves between patients achieving a complete 
metabolic response and those who did not. Of considerable importance was the worse overall 
survival in patients who did not achieve a complete metabolic response. With a five-times 
increased risk of death in these patients on multivariate analysis, and 16% of this population 
dying within just 2·5 years of the end of induction (13% due to their lymphoma), this finding  
suggests  PET  status  as  an  early  predictor  of decreased overall survival in this disease. 
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With better predictive ability than CT-based response assessment, PET status could be 
used to guide patients in making important life decisions and to assist physicians in 
determining the frequency of clinical follow-up. 
This study has a few limitations. We acknowledge that the Lugano 2014 analysis was 
performed retrospectively in response to updated international guidelines and that valid  
per-protocol PET scans were only available in half of the follicular lymphoma population from 
GALLIUM. We also acknowledge that there was a higher frequency of CT scans during the 
2-year maintenance period of the GALLIUM study than would currently be considered 
standard of care. Another limitation of this study is the effect on management of patients 
with stable disease, who were not mandated antibody maintenance. However, only four 
patients in the PET population had stable disease by CT as assessed by investigators, three of 
whom also received maintenance therapy, which suggests little effect on the results. 
When assessing the GALLIUM data in the context of earlier research, we note 
findings from a previous retrospective pooled analysis
5 of three multicentre studies, 
consisting of patients with follicular lymphoma predominantly treated with rituximab and 
CHOP without maintenance therapy, showing that the 17% (41/246) of patients who remained 
PET-positive (with scores of 4–5 on the 5-point scale) had worse progression-free survival than 
those who became PET-negative. The 12% (60/508) of patients in the landmark population of 
GALLIUM who did not obtain complete metabolic response at the end-of-induction 
landmark had a median progression-free survival of approximately 32 months, despite the use 
of maintenance. Similarly, although the absolute number of patient deaths during early 
follow-up was low, the worse overall survival of patients who did not obtain complete 
metabolic response in GALLIUM is consistent with the decreased overall survival 
documented previously. 
There was no difference between the proportion of patients achieving a complete 
metabolic response according to Lugano 2014 response criteria when comparing those treated 
with obinutuzumab-based chemotherapy and those who received rituximab-based 
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chemotherapy. No difference in end-of-induction complete metabolic response between the 
three chemotherapy backbones was observed.
16 However, we note that GALLIUM was not 
designed to compare differences between the different chemotherapy backbones.
16 
Faced with a heterogeneous disease, clinicians treating follicular lymphoma have 
previously lacked robust and clinically useful early post-induction predictors of survival. 
With modern immunochemotherapy, the median progression-free survival after first-line 
therapy and maintenance is estimated to be approximately 10 years,
17 making progression-free 
survival per se an increasingly impractical endpoint in clinical trials, which require more than 
1000 participants and several years of follow-up to demonstrate incremental advances.
18 
Similarly, overall survival is not a feasible primary endpoint in this setting. Although 
studies published since 2015 have shown the value of disease progression within 2 years of 
diagnosis and 30-month complete response on CT as prognostic indicators,
18–21 both 
parameters require an extended waiting time before they can be applied. By contrast, end-of-
induction PET status provides clinicians with an immediate marker of prognosis at a 
timepoint when there is potential to study early intervention approaches. It will be important 
to conduct a formal trial-level surrogacy analysis of pooled data from the GALLIUM study 
and other prospective studies to confirm if PET response assessment can be used as an 
earlier surrogate for progression-free and overall survival, and thus can become a legitimate 
primary endpoint in trials of first-line therapy for follicular lymphoma. Given the cost 
implications, inconvenience, and radiation dose concerns, the undertaking of both full-dose, 
contrast-enhanced CT and PET scanning after first-line therapy is impractical for most patients 
with follicular lymphoma. Furthermore, with cumbersome calculations to compare up to six 
target lesions, CT scans are rarely reported in accordance with formal response assessment 
criteria in routine clinical practice. Our results suggest that combined PET–low-dose CT is the 
preferred imaging that should  be done in patients after initial immunochemotherapy to 
assess response. Contrast-enhanced CT at end of induction should, therefore, be reserved only 
for the small number of patients requiring subsequent radiotherapy. Bone marrow biopsy 
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was required in GALLIUM only to confirm a CT-based complete response after induction 
therapy. Of this population, the incidence of persisting bone marrow involvement was 
documented in 2% of patients achieving a complete metabolic response, suggesting little 
additional value of bone marrow biopsy in this population. Our data  suggest that prognostic 
value could be obtained with PET alone for the purposes of clinical decision-making. 
Notwithstanding this finding, minimal residual disease analysis is showing some promise as a 
prognostic tool in follicular lymphoma,
22–24 and a future combined analysis of PET and 
minimal residual disease from GALLIUM
25 might provide additional prognostic value. 
Nevertheless, there are concerns that the lack of sensitivity of minimal residual disease 
markers, multicompartmental nature of follicular lymphoma, and complexity of this 
expensive and time-consuming detection technique might preclude the implementation of 
minimal residual disease detection as a prognostic tool beyond clinical trials. 
There is a growing body of evidence to suggest that quantitative PET measures could 
be prognostic in follicular lymphoma.26,27 Analysis of baseline total metabolic tumour volume, 
incorporated with pretreatment prognostic indices and metabolic response, might increase 
separation between the progression-free survival curves of the patients with or without a 
complete metabolic response, specifically to better identify the 10–15% of patients with 
complete metabolic response who do progress early. Further PET analyses might also contribute 
to improved understanding of why some patients without complete metabolic response do not 
progress early, particularly the obinutuzumab-treated population, for whom we hypothesise that 
residual 18F-FDG-avidity could reflect inflammation related to ongoing antibody-dependent 
cellular cytotoxicity (one of the mechanisms of action of obinutuzumab)28,29 immediately after 
induction therapy. Future studies of sequential PET scans in the months following 
obinutuzumab chemotherapy induction might show a similar effect and clarify the optimal time 
for PET assessment after obinutuzumab-based therapy. 
In conclusion, these data suggest that PET is a better assessment modality than contrast-
enhanced CT in patients with follicular lymphoma treated with first-line immunochemotherapy. 
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Further studies, combining PET with other prognostic tools, might help to identify patients at 
high risk of both relapse and early death to optimise risk-adapted follow-up. Although 
additional validation is required, PET might be a useful, early surrogate marker of progression-
free and overall survival in clinical trials, and provide the platform to guide response-adapted 
therapy in follicular lymphoma. 
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Tables and figures 
 
 
Table 1: Patient demographics and baseline characteristics 
 
 
 
 
 
 
 
 
 
 
PET population (n=595) 
Age, years 
Sex 
Male 
Female 
Ann Arbor stage at diagnosis 
I 
II 
III 
IV 
Missing 
FLIPI risk category, number of adverse factors 
Low (0–1) 
Intermediate (2) 
High (≥3) 
FLIPI2 risk category, number of adverse factors 
Low (0–1) 
Intermediate (2) 
High (≥3) 
Bone marrow involvement 
Bulky disease (≥7 cm) 
Time from initial diagnosis to randomisation, 
months 
Chemotherapy regimen 
Bendamustine 
CHOP 
CVP 
56 (48–65) 
Non-PET population 
(n=607) 
60 (51–67) 
270 (45%) 
325 (55%) 
293 (48%) 
314 (52%) 
9 (2%) 
41 (7%) 
201 (34%) 
340 (57%) 
4 (<1%) 
9 (1%) 
44 (7%) 
216 (36%) 
335 (55%) 
3 (<1%) 
124 (21%) 
233 (39%) 
238 (40%) 
128 (21%) 
215 (35%) 
264 (43%) 
54 (9%) 
289 (49%) 
234 (39%) 
320/591 (54%) 
269/594 (45%) 
1·5 (0·89–2·99)* 
52 (9%) 
295 (49%) 
241 (40%) 
293/599 (49%) 
257/606 (42%) 
1·5 (0·85–4·80)† 
338 (57%) 
206 (35%) 
51 (9%) 
348 (57%) 
192 (32%) 
67 (11%) 
Data are median (IQR), n (%), or n/N (%). CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone. 
CVP=cyclophosphamide, vincristine, and prednisone. FLIPI=Follicular Lymphoma International Prognostic Index. 
*n=593 (patient data missing from FLIPI2). †n=606 (patient data missing from FLIPI2).   
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Table 2: Patients with IRC-assessed response at end of induction by imaging technique, 
response criteria, and treatment group. 
 
 
 
 
 
 
 
 
Table 3: IRC-assessed response at end of induction per treatment group. 
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Table 4: Cox multivariate and univariate analyses for progression-free survival and 
overall survival in the landmark analysis populations. 
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Figure 1: Study profile 
IHP=International Harmonisation Project. IRC=independent review committee. *All patients 
with a baseline PET showing at least one PET-avid lesion were included in the PET 
population. †No valid IRC end-of-induction CT or end-of-induction visit after maintenance 
started. ‡Valid IRC end-of-induction CT or end-of-induction visit after maintenance started. 
§Valid IRC end-of-induction PET or end-of-induction visit after maintenance started. ¶Paired 
baseline and end-of-induction visit after maintenance started. 
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Figure 2: Landmark analysis of progression-free survival by IRC-assessed response 
status at end of induction therapy  
Figure shows progression-free survival at 2·5 years (vertical dashed line) and 95% CIs by 
complete response status by CT as per IHP 2007 response criteria (A), complete response 
status by PET according to IHP 2007 criteria (B), and complete metabolic response status 
assessed by Lugano 2014 criteria (C). HR=hazard ratio. IHP=International Harmonisation 
Project. IRC=independent review committee. 
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Figure 3: Landmark analysis of overall survival by IRC-assessed metabolic response 
status at end of induction therapy 
2·5-year timepoint (vertical dashed line) and 95% CIs are shown. PET metabolic response 
was assessed as per Lugano 2014 response criteria. IRC=independent review committee. 
HR=hazard ratio. 
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Figure 4: Landmark analysis of progression-free survival by IRC-assessed response 
status at end of induction therapy 
2·5-year progression-free survival (vertical dashed line) and 95% CIs are shown. Complete 
responses were assessed on CT scans as per International Harmonisation Project 2007 
response criteria and complete metabolic responses on PET scans as per Lugano 2014 
response criteria. HR=hazard ratio. IRC=independent review committee. 
 
 
  
